Biotechnology company Mediar Therapeutics has enlisted the support of CRO Qureight in the Phase II trial of a treatment for systemic sclerosis. 

Qureight’s AI 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase II EncompaSSc clinical trial. The trial will evaluate MTX-474, a monoclonal antibody therapeutic for people with diffuse cutaneous systemic sclerosis (dcSSc). 

Systemic sclerosis is a complex disease characterised by fibrosis, vasculopathy and inflammation in the lungs, skin and other vital organs. It is associated with high morbidity and mortality and there is a critical need to develop new therapeutics that effectively halt disease progression. 

During the trial, Qureight will use its platform to analyse High-Resolution Computed Tomography (HRCT) images taken of participants’ lungs at screening, and later at 24 weeks after treatment with MTX-474. Using precise quantitative imaging analytics of compartment-specific lung biomarkers, Qureight aims to provide a comprehensive view of changes within the lungs. 

The study aims to enrol participants with dcSSc, who will be randomly assigned in a 3:2 ratio to receive MTX-474 or a matching placebo by intravenous infusion. Treatment with MTX-474 will be given every four weeks. 

“We are dedicated to changing the landscape of treatment approaches for fibrotic diseases, including systemic sclerosis, to drive real impact on patient outcomes,” said Jeff Bornstein, Chief Medical Officer of Mediar Therapeutics. 

“We are excited to work with Qureight on this Phase II trial of MTX-474, building on the success in Phase I. Qureight’s AI-driven imaging endpoints provide deeper insights into lung fibrosis in complex diseases, such as systemic sclerosis.” 

“We’re proud to have been selected by Mediar Therapeutics to support this important systemic sclerosis study,” added Jessica Payne, Chief Commercial Officer at Qureight.  

“Our AI-powered imaging platform delivers analysis beyond traditional metrics, providing precise, compartment-specific insights into lung disease.”